EDG-5 Inhibitors
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
JTE 013 | 383150-41-2 | sc-203615 | 10 mg | $195.00 | 5 | |
JTE 013, an EDG-5, showcases unique reactivity as an acid halide, characterized by its ability to engage in nucleophilic acyl substitution reactions. Its electrophilic carbonyl group facilitates rapid interactions with nucleophiles, promoting diverse synthetic pathways. The compound's steric properties influence its selectivity in reactions, while its polar functional groups enhance solubility in organic solvents, allowing for efficient incorporation into various chemical processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor. While its main targets are BCR-ABL, c-KIT, and PDGFR, it may have off-target effects that influence S1PR2 signaling and expression, as these pathways are interconnected in cellular networks. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is another tyrosine kinase inhibitor, and like imatinib, it can have broad effects on cellular signaling. Its potential influence on S1PR2 expression may arise from its modulation of related signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation. Given the complex network of signaling pathways in cells, inhibition of mTOR may indirectly affect S1PR2 expression levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY-294002 is a PI3 kinase inhibitor. Since PI3K signaling can be downstream of S1PR2, inhibiting this pathway might reduce the functional effects of S1PR2, potentially leading to a decrease in its expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3 kinase inhibitor. By blocking PI3K signaling, it could indirectly affect S1PR2 activity and expression, contributing to altered cellular responses. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor, targeting several tyrosine protein kinases. Its complex effects on cell signaling might extend to pathways related to S1PR2, potentially influencing its expression. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor with potential indirect effects on S1PR2 expression through modulation of related signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK is part of the MAPK pathway, which is involved in various cellular processes. Inhibition of JNK could lead to changes in S1PR2 expression through alterations in cellular signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, affecting the MAPK/ERK pathway. This pathway is intricately connected to various receptors and signaling cascades, and its inhibition could indirectly influence S1PR2 expression. | ||||||